Regulatory approval

Published by the Health Service Executive. Approved

Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

This is written in the approval document.

Reimbursement

ODMS

Citation

Obinutuzumab and Bendamustine Therapy - 28 day cycle, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) CD20 + Follicular Lymphoma Bendamustine, Obinutuzumab